NASDAQ$ZYME
Zymeworks Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Zymeworks reported its financial results for the second quarter of 2024, highlighting progress in its clinical development programs and a strong cash position.
Zymeworks reported a net loss of $37.686 million for Q2 2024, an improvement from the $51.152 million loss in Q2 2023. Revenue from research and development collaborations was $19.243 million, significantly up from $7.002 million in the prior year. The company ended the quarter with $395.9 million in cash resources, projecting a cash runway into the second half of 2027.
- Reported $395.9 million in cash resources as of June 30, 2024, providing projected cash runway into 2H 2027.
- FDA granted Priority Review for zanidatamab BLA as second-line treatment for HER2-positive biliary tract cancers (BTC) with a target action date of November 29, 2024.
- IND applications for ZW191 and ZW171 cleared by FDA, with first-in-human studies planned to initiate in 2H 2024.
- Discontinued clinical development program for zanidatamab zovodotin (ZW49) to focus on early-stage, best-in-class programs.
Headline financials
Revenue & EPS history
Zymeworks · Revenue · Quarterly
$19.2M
Forward guidance
Zymeworks anticipates continued progress in its clinical pipeline, with planned initiations of Phase 1 dose escalation studies for ZW171 and ZW191 in 2H 2024. The company expects its existing cash resources, combined with anticipated regulatory milestone payments, to fund operations into the second half of 2027.
Tailwinds
- Projected cash runway into 2H 2027 with current cash resources and anticipated milestone payments.
- Initiation of Phase 1 dose escalation studies for ZW171 and ZW191 in 2H 2024 in multiple jurisdictions.
- Continued advancement of IND-enabling studies for preclinical candidates ZW220 and ZW251, with IND filings scheduled for 2025.
- Ongoing pivotal HERIZON-GEA-01 trial for zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) with top-line progression-free survival data expected in 2Q25.
- Exploration of partnering discussions for zanidatamab zovodotin to provide complementary coverage for NSCLC, breast cancer, and other indications.
Headwinds
- Discontinuation of the clinical development program for zanidatamab zovodotin (ZW49).
- Reliance on anticipated regulatory milestone payments to extend cash runway.
- Potential for delays in clinical trials or regulatory approvals.
- Market conditions and other external factors could impact business and financial performance.
- Inability to maintain or enter into new partnerships or strategic collaborations could affect future development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q2 2024
-1.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.6%
Avg return
30 days after
38%
5 / 13 earnings
Positive
+1.4%
Q1 2023
Best reaction
-8.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -13.5% | -13.0% | |
| Q4 2025 | +0.1% | +3.4% | +11.4% | |
| Q3 2025 | -8.0% | +8.2% | +49.1% | |
| Q1 2025 | -0.1% | -0.6% | +11.3% | |
| Q4 2024 | -8.0% | -11.2% | -16.9% | |
| Q3 2024 | +1.0% | +1.2% | +11.7% | |
| Q2 2024 | +0.0% | +4.3% | +22.4% | |
| Q1 2024 | +0.0% | -8.3% | -18.4% | |
| Q4 2023 | +0.0% | +1.6% | +3.8% | |
| Q3 2023 | +1.2% | +0.1% | +31.2% | |
| Q3 2021 | +0.0% | -1.3% | +10.3% | |
| Q2 2023 | +0.8% | -3.6% | -7.5% | |
| Q1 2023 | +1.4% | +14.1% | +2.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro